Literature DB >> 18625409

Glial cells in ALS: the missing link?

Elsa Raibon1, Lisa Marie Todd, Thomas Möller.   

Abstract

Amyotrophic lateral sclerosis (ALS) was initially known as Charcot's sclerosis, named after the French neurobiologist and physician Jean-Martin Charcot who first described this type of muscular atrophy in the early nineteenth century. In the United States, ALS became widely known as Lou Gehrig's disease after the famous baseball player who succumbed to the disease in the late 1930s. Currently, ALS is the most common motor neuron disease, with a worldwide incidence of 8 cases per 100,000 population per year. Familial forms constitute approximately 5% to 10% of all cases. Onset increases with age, with a peak in the seventh decade and a slight preponderance (relative risk, 1.3-1.5) among men compared with women. Rapid progression of motor neuron loss leads to death an average of 3 to 5 years after symptom onset. The cause of ALS remains unknown and there is still no curative therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625409     DOI: 10.1016/j.pmr.2008.04.003

Source DB:  PubMed          Journal:  Phys Med Rehabil Clin N Am        ISSN: 1047-9651            Impact factor:   1.784


  3 in total

1.  Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction.

Authors:  Kiyoshi Kikuchi; Ko-Ichi Kawahara; Hisaaki Uchikado; Naohisa Miyagi; Terukazu Kuramoto; Tomoya Miyagi; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Naoki Miura; Kazunori Takenouchi; Yoko Oyama; Binita Shrestha; Fumiyo Matsuda; Yoshihiro Yoshida; Shinihiro Arimura; Kentaro Mera; Ko-Ichi Tada; Narimasa Yoshinaga; Ryuichi Maenosono; Yoshiko Ohno; Teruto Hashiguchi; Ikuro Maruyama; Minoru Shigemori
Journal:  Exp Ther Med       Date:  2011-06-07       Impact factor: 2.447

Review 2.  Ventilatory control in ALS.

Authors:  Nicole L Nichols; J Van Dyke; L Nashold; I Satriotomo; M Suzuki; G S Mitchell
Journal:  Respir Physiol Neurobiol       Date:  2013-05-18       Impact factor: 1.931

3.  Long-term interleukin-33 treatment delays disease onset and alleviates astrocytic activation in a transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  Paula Korhonen; Eveliina Pollari; Katja M Kanninen; Ekaterina Savchenko; Šárka Lehtonen; Sara Wojciechowski; Yuriy Pomeshchik; Ludo Van Den Bosch; Gundars Goldsteins; Jari Koistinaho; Tarja Malm
Journal:  IBRO Rep       Date:  2019-01-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.